RNA
Atrium Therapeutics, Inc. Common Stock
NASDAQ: RNA · HEALTHCARE · BIOTECHNOLOGY
$8.40
+0.96% today
Updated 2026-10-28
Market cap
$131.20M
P/E ratio
—
P/S ratio
3.66x
EPS (TTM)
$-5.44
Dividend yield
—
52W range
$8 – $17
Volume
0.3M
Atrium Therapeutics, Inc. Common Stock (RNA) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$8.40
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$556.78
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -184.10%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.